Simply Wall St.
We're Keeping An Eye On Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate
➖
AI Sentiment
Neutral
4/10
- Home
- AURA
as of 01-23-2026 3:42pm EST
$5.68
$0.07
-1.13%
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 318.8M | IPO Year: | 2021 |
| Target Price: | $20.20 | AVG Volume (30 days): | 197.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.34 - $8.27 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered AURA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Aura Biosciences Inc. (AURA)
de los Pinos Elisabet
Sell
See Remarks
AURA Jan 20, 2026
Avg Cost/Share
$4.86
Shares
16,928
Total Value
$82,270.08
Owned After
457,463
SEC Form 4
Elazzouzi Amy
Sell
Senior Vice President, Finance
AURA Jan 20, 2026
Avg Cost/Share
$4.86
Shares
1,581
Total Value
$7,683.66
Owned After
84,081
SEC Form 4
Hopkins Janet Jill
Sell
Chief Medical Officer
AURA Nov 17, 2025
Avg Cost/Share
$5.42
Shares
17,109
Total Value
$92,730.78
Owned After
252,685
SEC Form 4
de los Pinos Elisabet
Sell
See Remarks
AURA Oct 29, 2025
Avg Cost/Share
$6.35
Shares
9,049
Total Value
$57,461.15
Owned After
457,463
SEC Form 4
Elazzouzi Amy
Sell
Senior Vice President, Finance
AURA Oct 29, 2025
Avg Cost/Share
$6.35
Shares
896
Total Value
$5,689.60
Owned After
84,081
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| de los Pinos Elisabet | AURA | See Remarks | Jan 20, 2026 | Sell | $4.86 | 16,928 | $82,270.08 | 457,463 | |
| Elazzouzi Amy | AURA | Senior Vice President, Finance | Jan 20, 2026 | Sell | $4.86 | 1,581 | $7,683.66 | 84,081 | |
| Hopkins Janet Jill | AURA | Chief Medical Officer | Nov 17, 2025 | Sell | $5.42 | 17,109 | $92,730.78 | 252,685 | |
| de los Pinos Elisabet | AURA | See Remarks | Oct 29, 2025 | Sell | $6.35 | 9,049 | $57,461.15 | 457,463 | |
| Elazzouzi Amy | AURA | Senior Vice President, Finance | Oct 29, 2025 | Sell | $6.35 | 896 | $5,689.60 | 84,081 |
Latest Aura Biosciences Inc. News
AURA Breaking Stock News: Dive into AURA Ticker-Specific Updates for Smart Investing
Compare AURA vs Leading Stocks
See how AURA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AURA Aura Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.